nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Ezetimibe—atherosclerosis	0.159	0.211	CbGbCtD
Tapentadol—UGT2B7—Simvastatin—atherosclerosis	0.148	0.196	CbGbCtD
Tapentadol—UGT2B7—Lovastatin—atherosclerosis	0.145	0.192	CbGbCtD
Tapentadol—CYP2C19—Rosuvastatin—atherosclerosis	0.0338	0.0448	CbGbCtD
Tapentadol—CYP2C19—Simvastatin—atherosclerosis	0.0314	0.0417	CbGbCtD
Tapentadol—CYP2C19—Lovastatin—atherosclerosis	0.0307	0.0408	CbGbCtD
Tapentadol—CYP2D6—Niacin—atherosclerosis	0.0302	0.0401	CbGbCtD
Tapentadol—CYP2C9—Rosuvastatin—atherosclerosis	0.0281	0.0373	CbGbCtD
Tapentadol—CYP2C9—Simvastatin—atherosclerosis	0.0261	0.0347	CbGbCtD
Tapentadol—CYP2C9—Pravastatin—atherosclerosis	0.0256	0.0339	CbGbCtD
Tapentadol—CYP2C9—Lovastatin—atherosclerosis	0.0256	0.0339	CbGbCtD
Tapentadol—CYP2D6—Simvastatin—atherosclerosis	0.0239	0.0317	CbGbCtD
Tapentadol—CYP2D6—Lovastatin—atherosclerosis	0.0234	0.031	CbGbCtD
Tapentadol—CYP2D6—Pravastatin—atherosclerosis	0.0234	0.031	CbGbCtD
Tapentadol—Memory impairment—Ezetimibe—atherosclerosis	0.00191	0.0122	CcSEcCtD
Tapentadol—Lung disorder—Niacin—atherosclerosis	0.00185	0.0118	CcSEcCtD
Tapentadol—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00182	0.0116	CcSEcCtD
Tapentadol—Memory impairment—Simvastatin—atherosclerosis	0.00182	0.0116	CcSEcCtD
Tapentadol—Nightmare—Rosuvastatin—atherosclerosis	0.00174	0.0111	CcSEcCtD
Tapentadol—Feeling hot—Niacin—atherosclerosis	0.00167	0.0107	CcSEcCtD
Tapentadol—Memory impairment—Pravastatin—atherosclerosis	0.00164	0.0105	CcSEcCtD
Tapentadol—Drug interaction—Ezetimibe—atherosclerosis	0.00161	0.0103	CcSEcCtD
Tapentadol—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00157	0.01	CcSEcCtD
Tapentadol—Drug interaction—Simvastatin—atherosclerosis	0.00154	0.00984	CcSEcCtD
Tapentadol—Drug interaction—Pravastatin—atherosclerosis	0.00139	0.0089	CcSEcCtD
Tapentadol—Nightmare—Simvastatin—atherosclerosis	0.00138	0.00882	CcSEcCtD
Tapentadol—Nightmare—Pravastatin—atherosclerosis	0.00125	0.00797	CcSEcCtD
Tapentadol—Breast disorder—Rosuvastatin—atherosclerosis	0.00118	0.00756	CcSEcCtD
Tapentadol—Hot flush—Ezetimibe—atherosclerosis	0.00116	0.00743	CcSEcCtD
Tapentadol—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00115	0.00737	CcSEcCtD
Tapentadol—Depression—Rosuvastatin—atherosclerosis	0.001	0.00643	CcSEcCtD
Tapentadol—Hot flush—Pravastatin—atherosclerosis	0.001	0.00641	CcSEcCtD
Tapentadol—Menopausal symptoms—Pravastatin—atherosclerosis	0.000993	0.00635	CcSEcCtD
Tapentadol—Breast disorder—Ezetimibe—atherosclerosis	0.000982	0.00628	CcSEcCtD
Tapentadol—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000979	0.00626	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000979	0.00626	CcSEcCtD
Tapentadol—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000972	0.00622	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.000959	0.00613	CcSEcCtD
Tapentadol—Abdominal discomfort—Lovastatin—atherosclerosis	0.000918	0.00587	CcSEcCtD
Tapentadol—Erectile dysfunction—Lovastatin—atherosclerosis	0.000882	0.00564	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000873	0.00558	CcSEcCtD
Tapentadol—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000865	0.00553	CcSEcCtD
Tapentadol—Abdominal discomfort—Simvastatin—atherosclerosis	0.000859	0.00549	CcSEcCtD
Tapentadol—Nasopharyngitis—Pravastatin—atherosclerosis	0.000838	0.00536	CcSEcCtD
Tapentadol—Infestation—Ezetimibe—atherosclerosis	0.000838	0.00536	CcSEcCtD
Tapentadol—Infestation NOS—Ezetimibe—atherosclerosis	0.000838	0.00536	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000833	0.00532	CcSEcCtD
Tapentadol—Urinary tract infection—Lovastatin—atherosclerosis	0.00083	0.00531	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000826	0.00529	CcSEcCtD
Tapentadol—Erectile dysfunction—Simvastatin—atherosclerosis	0.000825	0.00528	CcSEcCtD
Tapentadol—Depression—Simvastatin—atherosclerosis	0.000796	0.00509	CcSEcCtD
Tapentadol—Mental disorder—Rosuvastatin—atherosclerosis	0.000792	0.00507	CcSEcCtD
Tapentadol—Erectile dysfunction—Niacin—atherosclerosis	0.000758	0.00485	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000753	0.00481	CcSEcCtD
Tapentadol—Erectile dysfunction—Pravastatin—atherosclerosis	0.000746	0.00477	CcSEcCtD
Tapentadol—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000739	0.00473	CcSEcCtD
Tapentadol—Weight decreased—Pravastatin—atherosclerosis	0.000733	0.00469	CcSEcCtD
Tapentadol—Depression—Pravastatin—atherosclerosis	0.00072	0.00461	CcSEcCtD
Tapentadol—Angioedema—Rosuvastatin—atherosclerosis	0.000719	0.0046	CcSEcCtD
Tapentadol—Urinary tract infection—Pravastatin—atherosclerosis	0.000702	0.00449	CcSEcCtD
Tapentadol—Chills—Lovastatin—atherosclerosis	0.000688	0.0044	CcSEcCtD
Tapentadol—Cough—Rosuvastatin—atherosclerosis	0.000687	0.00439	CcSEcCtD
Tapentadol—Angiopathy—Ezetimibe—atherosclerosis	0.000682	0.00436	CcSEcCtD
Tapentadol—Immune system disorder—Ezetimibe—atherosclerosis	0.000679	0.00434	CcSEcCtD
Tapentadol—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000678	0.00433	CcSEcCtD
Tapentadol—Arthralgia—Rosuvastatin—atherosclerosis	0.00067	0.00429	CcSEcCtD
Tapentadol—Mental disorder—Ezetimibe—atherosclerosis	0.000659	0.00421	CcSEcCtD
Tapentadol—Hypoaesthesia—Niacin—atherosclerosis	0.000655	0.00419	CcSEcCtD
Tapentadol—Malnutrition—Ezetimibe—atherosclerosis	0.000654	0.00419	CcSEcCtD
Tapentadol—Confusional state—Rosuvastatin—atherosclerosis	0.000648	0.00414	CcSEcCtD
Tapentadol—Hypoaesthesia—Pravastatin—atherosclerosis	0.000645	0.00413	CcSEcCtD
Tapentadol—Chills—Simvastatin—atherosclerosis	0.000643	0.00411	CcSEcCtD
Tapentadol—Infection—Rosuvastatin—atherosclerosis	0.000638	0.00408	CcSEcCtD
Tapentadol—Visual impairment—Niacin—atherosclerosis	0.000634	0.00406	CcSEcCtD
Tapentadol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00063	0.00403	CcSEcCtD
Tapentadol—Vision blurred—Lovastatin—atherosclerosis	0.000629	0.00402	CcSEcCtD
Tapentadol—Mental disorder—Simvastatin—atherosclerosis	0.000628	0.00402	CcSEcCtD
Tapentadol—Tremor—Lovastatin—atherosclerosis	0.000625	0.004	CcSEcCtD
Tapentadol—Visual impairment—Pravastatin—atherosclerosis	0.000625	0.004	CcSEcCtD
Tapentadol—Eye disorder—Niacin—atherosclerosis	0.000615	0.00394	CcSEcCtD
Tapentadol—Angioedema—Lovastatin—atherosclerosis	0.00061	0.0039	CcSEcCtD
Tapentadol—Cardiac disorder—Pravastatin—atherosclerosis	0.000602	0.00385	CcSEcCtD
Tapentadol—Vertigo—Lovastatin—atherosclerosis	0.0006	0.00383	CcSEcCtD
Tapentadol—Angioedema—Ezetimibe—atherosclerosis	0.000598	0.00382	CcSEcCtD
Tapentadol—Angiopathy—Niacin—atherosclerosis	0.000597	0.00382	CcSEcCtD
Tapentadol—Chills—Niacin—atherosclerosis	0.000591	0.00378	CcSEcCtD
Tapentadol—Vision blurred—Simvastatin—atherosclerosis	0.000588	0.00376	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000585	0.00374	CcSEcCtD
Tapentadol—Tremor—Simvastatin—atherosclerosis	0.000585	0.00374	CcSEcCtD
Tapentadol—Chills—Pravastatin—atherosclerosis	0.000582	0.00372	CcSEcCtD
Tapentadol—Insomnia—Rosuvastatin—atherosclerosis	0.000581	0.00372	CcSEcCtD
Tapentadol—Palpitations—Ezetimibe—atherosclerosis	0.000578	0.0037	CcSEcCtD
Tapentadol—Paraesthesia—Rosuvastatin—atherosclerosis	0.000577	0.00369	CcSEcCtD
Tapentadol—Malnutrition—Niacin—atherosclerosis	0.000573	0.00367	CcSEcCtD
Tapentadol—Cough—Ezetimibe—atherosclerosis	0.000571	0.00365	CcSEcCtD
Tapentadol—Angioedema—Simvastatin—atherosclerosis	0.00057	0.00365	CcSEcCtD
Tapentadol—Arthralgia—Lovastatin—atherosclerosis	0.000568	0.00363	CcSEcCtD
Tapentadol—Anxiety—Lovastatin—atherosclerosis	0.000566	0.00362	CcSEcCtD
Tapentadol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000566	0.00362	CcSEcCtD
Tapentadol—Tension—Niacin—atherosclerosis	0.000562	0.0036	CcSEcCtD
Tapentadol—Vertigo—Simvastatin—atherosclerosis	0.000561	0.00359	CcSEcCtD
Tapentadol—Arthralgia—Ezetimibe—atherosclerosis	0.000557	0.00356	CcSEcCtD
Tapentadol—Nervousness—Niacin—atherosclerosis	0.000557	0.00356	CcSEcCtD
Tapentadol—Dry mouth—Lovastatin—atherosclerosis	0.000556	0.00355	CcSEcCtD
Tapentadol—Tension—Pravastatin—atherosclerosis	0.000554	0.00354	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000553	0.00354	CcSEcCtD
Tapentadol—Constipation—Rosuvastatin—atherosclerosis	0.00055	0.00351	CcSEcCtD
Tapentadol—Confusional state—Lovastatin—atherosclerosis	0.000549	0.00351	CcSEcCtD
Tapentadol—Nervousness—Pravastatin—atherosclerosis	0.000548	0.00351	CcSEcCtD
Tapentadol—Dry mouth—Ezetimibe—atherosclerosis	0.000545	0.00349	CcSEcCtD
Tapentadol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000545	0.00348	CcSEcCtD
Tapentadol—Infection—Lovastatin—atherosclerosis	0.000541	0.00346	CcSEcCtD
Tapentadol—Vision blurred—Niacin—atherosclerosis	0.00054	0.00345	CcSEcCtD
Tapentadol—Confusional state—Ezetimibe—atherosclerosis	0.000539	0.00344	CcSEcCtD
Tapentadol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000534	0.00342	CcSEcCtD
Tapentadol—Vision blurred—Pravastatin—atherosclerosis	0.000532	0.0034	CcSEcCtD
Tapentadol—Arthralgia—Simvastatin—atherosclerosis	0.000531	0.0034	CcSEcCtD
Tapentadol—Infection—Ezetimibe—atherosclerosis	0.000531	0.00339	CcSEcCtD
Tapentadol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00053	0.00339	CcSEcCtD
Tapentadol—Anxiety—Simvastatin—atherosclerosis	0.00053	0.00339	CcSEcCtD
Tapentadol—Tremor—Pravastatin—atherosclerosis	0.000529	0.00338	CcSEcCtD
Tapentadol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000524	0.00335	CcSEcCtD
Tapentadol—Angioedema—Niacin—atherosclerosis	0.000524	0.00335	CcSEcCtD
Tapentadol—Skin disorder—Ezetimibe—atherosclerosis	0.000519	0.00332	CcSEcCtD
Tapentadol—Angioedema—Pravastatin—atherosclerosis	0.000516	0.0033	CcSEcCtD
Tapentadol—Vertigo—Niacin—atherosclerosis	0.000515	0.00329	CcSEcCtD
Tapentadol—Syncope—Niacin—atherosclerosis	0.000514	0.00329	CcSEcCtD
Tapentadol—Confusional state—Simvastatin—atherosclerosis	0.000514	0.00329	CcSEcCtD
Tapentadol—Urticaria—Rosuvastatin—atherosclerosis	0.000511	0.00327	CcSEcCtD
Tapentadol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000509	0.00326	CcSEcCtD
Tapentadol—Oedema—Simvastatin—atherosclerosis	0.000509	0.00326	CcSEcCtD
Tapentadol—Vertigo—Pravastatin—atherosclerosis	0.000507	0.00324	CcSEcCtD
Tapentadol—Palpitations—Niacin—atherosclerosis	0.000506	0.00324	CcSEcCtD
Tapentadol—Infection—Simvastatin—atherosclerosis	0.000506	0.00324	CcSEcCtD
Tapentadol—Loss of consciousness—Niacin—atherosclerosis	0.000504	0.00322	CcSEcCtD
Tapentadol—Cough—Niacin—atherosclerosis	0.0005	0.0032	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000496	0.00317	CcSEcCtD
Tapentadol—Insomnia—Lovastatin—atherosclerosis	0.000493	0.00315	CcSEcCtD
Tapentadol—Cough—Pravastatin—atherosclerosis	0.000492	0.00315	CcSEcCtD
Tapentadol—Paraesthesia—Lovastatin—atherosclerosis	0.000489	0.00313	CcSEcCtD
Tapentadol—Arthralgia—Niacin—atherosclerosis	0.000488	0.00312	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000487	0.00311	CcSEcCtD
Tapentadol—Dyspnoea—Lovastatin—atherosclerosis	0.000486	0.00311	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000485	0.0031	CcSEcCtD
Tapentadol—Insomnia—Ezetimibe—atherosclerosis	0.000483	0.00309	CcSEcCtD
Tapentadol—Arthralgia—Pravastatin—atherosclerosis	0.00048	0.00307	CcSEcCtD
Tapentadol—Paraesthesia—Ezetimibe—atherosclerosis	0.00048	0.00307	CcSEcCtD
Tapentadol—Dyspepsia—Lovastatin—atherosclerosis	0.000479	0.00307	CcSEcCtD
Tapentadol—Anxiety—Pravastatin—atherosclerosis	0.000479	0.00306	CcSEcCtD
Tapentadol—Dry mouth—Niacin—atherosclerosis	0.000477	0.00305	CcSEcCtD
Tapentadol—Dyspnoea—Ezetimibe—atherosclerosis	0.000476	0.00305	CcSEcCtD
Tapentadol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000473	0.00303	CcSEcCtD
Tapentadol—Decreased appetite—Lovastatin—atherosclerosis	0.000473	0.00303	CcSEcCtD
Tapentadol—Dyspepsia—Ezetimibe—atherosclerosis	0.00047	0.00301	CcSEcCtD
Tapentadol—Fatigue—Lovastatin—atherosclerosis	0.00047	0.003	CcSEcCtD
Tapentadol—Anaphylactic shock—Niacin—atherosclerosis	0.000468	0.00299	CcSEcCtD
Tapentadol—Oedema—Niacin—atherosclerosis	0.000468	0.00299	CcSEcCtD
Tapentadol—Constipation—Lovastatin—atherosclerosis	0.000466	0.00298	CcSEcCtD
Tapentadol—Confusional state—Pravastatin—atherosclerosis	0.000464	0.00297	CcSEcCtD
Tapentadol—Decreased appetite—Ezetimibe—atherosclerosis	0.000464	0.00297	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000464	0.00297	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Asthenia—Rosuvastatin—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Insomnia—Simvastatin—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Oedema—Pravastatin—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Fatigue—Ezetimibe—atherosclerosis	0.000461	0.00295	CcSEcCtD
Tapentadol—Shock—Niacin—atherosclerosis	0.00046	0.00294	CcSEcCtD
Tapentadol—Infection—Pravastatin—atherosclerosis	0.000458	0.00293	CcSEcCtD
Tapentadol—Paraesthesia—Simvastatin—atherosclerosis	0.000457	0.00293	CcSEcCtD
Tapentadol—Constipation—Ezetimibe—atherosclerosis	0.000457	0.00292	CcSEcCtD
Tapentadol—Tachycardia—Niacin—atherosclerosis	0.000456	0.00292	CcSEcCtD
Tapentadol—Pruritus—Rosuvastatin—atherosclerosis	0.000455	0.00291	CcSEcCtD
Tapentadol—Skin disorder—Niacin—atherosclerosis	0.000454	0.00291	CcSEcCtD
Tapentadol—Dyspnoea—Simvastatin—atherosclerosis	0.000454	0.0029	CcSEcCtD
Tapentadol—Hyperhidrosis—Niacin—atherosclerosis	0.000452	0.00289	CcSEcCtD
Tapentadol—Feeling abnormal—Lovastatin—atherosclerosis	0.000449	0.00287	CcSEcCtD
Tapentadol—Dyspepsia—Simvastatin—atherosclerosis	0.000448	0.00287	CcSEcCtD
Tapentadol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000445	0.00285	CcSEcCtD
Tapentadol—Decreased appetite—Simvastatin—atherosclerosis	0.000443	0.00283	CcSEcCtD
Tapentadol—Feeling abnormal—Ezetimibe—atherosclerosis	0.00044	0.00282	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00044	0.00281	CcSEcCtD
Tapentadol—Diarrhoea—Rosuvastatin—atherosclerosis	0.00044	0.00281	CcSEcCtD
Tapentadol—Fatigue—Simvastatin—atherosclerosis	0.000439	0.00281	CcSEcCtD
Tapentadol—Hypotension—Niacin—atherosclerosis	0.000437	0.0028	CcSEcCtD
Tapentadol—Constipation—Simvastatin—atherosclerosis	0.000436	0.00279	CcSEcCtD
Tapentadol—Urticaria—Lovastatin—atherosclerosis	0.000433	0.00277	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000426	0.00273	CcSEcCtD
Tapentadol—Dizziness—Rosuvastatin—atherosclerosis	0.000425	0.00272	CcSEcCtD
Tapentadol—Urticaria—Ezetimibe—atherosclerosis	0.000424	0.00271	CcSEcCtD
Tapentadol—Insomnia—Niacin—atherosclerosis	0.000423	0.00271	CcSEcCtD
Tapentadol—Paraesthesia—Niacin—atherosclerosis	0.00042	0.00269	CcSEcCtD
Tapentadol—Feeling abnormal—Simvastatin—atherosclerosis	0.00042	0.00268	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00042	0.00268	CcSEcCtD
Tapentadol—Dyspnoea—Niacin—atherosclerosis	0.000417	0.00267	CcSEcCtD
Tapentadol—Insomnia—Pravastatin—atherosclerosis	0.000417	0.00266	CcSEcCtD
Tapentadol—Somnolence—Niacin—atherosclerosis	0.000416	0.00266	CcSEcCtD
Tapentadol—Paraesthesia—Pravastatin—atherosclerosis	0.000414	0.00264	CcSEcCtD
Tapentadol—Dyspepsia—Niacin—atherosclerosis	0.000412	0.00263	CcSEcCtD
Tapentadol—Dyspnoea—Pravastatin—atherosclerosis	0.000411	0.00263	CcSEcCtD
Tapentadol—Decreased appetite—Niacin—atherosclerosis	0.000407	0.0026	CcSEcCtD
Tapentadol—Dyspepsia—Pravastatin—atherosclerosis	0.000405	0.00259	CcSEcCtD
Tapentadol—Rash—Rosuvastatin—atherosclerosis	0.000405	0.00259	CcSEcCtD
Tapentadol—Dermatitis—Rosuvastatin—atherosclerosis	0.000405	0.00259	CcSEcCtD
Tapentadol—Urticaria—Simvastatin—atherosclerosis	0.000405	0.00259	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000404	0.00258	CcSEcCtD
Tapentadol—Headache—Rosuvastatin—atherosclerosis	0.000403	0.00257	CcSEcCtD
Tapentadol—Hypersensitivity—Lovastatin—atherosclerosis	0.000401	0.00257	CcSEcCtD
Tapentadol—Decreased appetite—Pravastatin—atherosclerosis	0.0004	0.00256	CcSEcCtD
Tapentadol—Fatigue—Pravastatin—atherosclerosis	0.000397	0.00254	CcSEcCtD
Tapentadol—Constipation—Pravastatin—atherosclerosis	0.000394	0.00252	CcSEcCtD
Tapentadol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000394	0.00252	CcSEcCtD
Tapentadol—Asthenia—Lovastatin—atherosclerosis	0.000391	0.0025	CcSEcCtD
Tapentadol—Pruritus—Lovastatin—atherosclerosis	0.000385	0.00246	CcSEcCtD
Tapentadol—Asthenia—Ezetimibe—atherosclerosis	0.000383	0.00245	CcSEcCtD
Tapentadol—Nausea—Rosuvastatin—atherosclerosis	0.000382	0.00244	CcSEcCtD
Tapentadol—Feeling abnormal—Pravastatin—atherosclerosis	0.00038	0.00243	CcSEcCtD
Tapentadol—Pruritus—Ezetimibe—atherosclerosis	0.000378	0.00242	CcSEcCtD
Tapentadol—Hypersensitivity—Simvastatin—atherosclerosis	0.000375	0.0024	CcSEcCtD
Tapentadol—Diarrhoea—Lovastatin—atherosclerosis	0.000373	0.00238	CcSEcCtD
Tapentadol—Urticaria—Niacin—atherosclerosis	0.000372	0.00238	CcSEcCtD
Tapentadol—Urticaria—Pravastatin—atherosclerosis	0.000366	0.00234	CcSEcCtD
Tapentadol—Asthenia—Simvastatin—atherosclerosis	0.000365	0.00234	CcSEcCtD
Tapentadol—Diarrhoea—Ezetimibe—atherosclerosis	0.000365	0.00234	CcSEcCtD
Tapentadol—Pruritus—Simvastatin—atherosclerosis	0.00036	0.00231	CcSEcCtD
Tapentadol—Dizziness—Lovastatin—atherosclerosis	0.00036	0.0023	CcSEcCtD
Tapentadol—Dizziness—Ezetimibe—atherosclerosis	0.000353	0.00226	CcSEcCtD
Tapentadol—Diarrhoea—Simvastatin—atherosclerosis	0.000349	0.00223	CcSEcCtD
Tapentadol—Vomiting—Lovastatin—atherosclerosis	0.000346	0.00221	CcSEcCtD
Tapentadol—Hypersensitivity—Niacin—atherosclerosis	0.000345	0.0022	CcSEcCtD
Tapentadol—Rash—Lovastatin—atherosclerosis	0.000343	0.0022	CcSEcCtD
Tapentadol—Dermatitis—Lovastatin—atherosclerosis	0.000343	0.00219	CcSEcCtD
Tapentadol—Headache—Lovastatin—atherosclerosis	0.000341	0.00218	CcSEcCtD
Tapentadol—Vomiting—Ezetimibe—atherosclerosis	0.00034	0.00217	CcSEcCtD
Tapentadol—Hypersensitivity—Pravastatin—atherosclerosis	0.000339	0.00217	CcSEcCtD
Tapentadol—Dizziness—Simvastatin—atherosclerosis	0.000337	0.00215	CcSEcCtD
Tapentadol—Rash—Ezetimibe—atherosclerosis	0.000337	0.00215	CcSEcCtD
Tapentadol—Dermatitis—Ezetimibe—atherosclerosis	0.000336	0.00215	CcSEcCtD
Tapentadol—Asthenia—Niacin—atherosclerosis	0.000336	0.00215	CcSEcCtD
Tapentadol—Headache—Ezetimibe—atherosclerosis	0.000335	0.00214	CcSEcCtD
Tapentadol—Pruritus—Niacin—atherosclerosis	0.000331	0.00212	CcSEcCtD
Tapentadol—Asthenia—Pravastatin—atherosclerosis	0.00033	0.00211	CcSEcCtD
Tapentadol—Pruritus—Pravastatin—atherosclerosis	0.000326	0.00208	CcSEcCtD
Tapentadol—Vomiting—Simvastatin—atherosclerosis	0.000324	0.00207	CcSEcCtD
Tapentadol—Nausea—Lovastatin—atherosclerosis	0.000323	0.00207	CcSEcCtD
Tapentadol—Rash—Simvastatin—atherosclerosis	0.000321	0.00205	CcSEcCtD
Tapentadol—Dermatitis—Simvastatin—atherosclerosis	0.000321	0.00205	CcSEcCtD
Tapentadol—Diarrhoea—Niacin—atherosclerosis	0.00032	0.00205	CcSEcCtD
Tapentadol—Headache—Simvastatin—atherosclerosis	0.000319	0.00204	CcSEcCtD
Tapentadol—Nausea—Ezetimibe—atherosclerosis	0.000317	0.00203	CcSEcCtD
Tapentadol—Diarrhoea—Pravastatin—atherosclerosis	0.000315	0.00202	CcSEcCtD
Tapentadol—Dizziness—Niacin—atherosclerosis	0.000309	0.00198	CcSEcCtD
Tapentadol—Dizziness—Pravastatin—atherosclerosis	0.000305	0.00195	CcSEcCtD
Tapentadol—Nausea—Simvastatin—atherosclerosis	0.000303	0.00194	CcSEcCtD
Tapentadol—Vomiting—Niacin—atherosclerosis	0.000297	0.0019	CcSEcCtD
Tapentadol—Rash—Niacin—atherosclerosis	0.000295	0.00189	CcSEcCtD
Tapentadol—Dermatitis—Niacin—atherosclerosis	0.000295	0.00188	CcSEcCtD
Tapentadol—Headache—Niacin—atherosclerosis	0.000293	0.00187	CcSEcCtD
Tapentadol—Vomiting—Pravastatin—atherosclerosis	0.000293	0.00187	CcSEcCtD
Tapentadol—Rash—Pravastatin—atherosclerosis	0.00029	0.00186	CcSEcCtD
Tapentadol—Dermatitis—Pravastatin—atherosclerosis	0.00029	0.00186	CcSEcCtD
Tapentadol—Headache—Pravastatin—atherosclerosis	0.000289	0.00185	CcSEcCtD
Tapentadol—Nausea—Niacin—atherosclerosis	0.000278	0.00178	CcSEcCtD
Tapentadol—Nausea—Pravastatin—atherosclerosis	0.000274	0.00175	CcSEcCtD
Tapentadol—UGT1A9—Metabolism—GPX1—atherosclerosis	1.61e-05	0.000179	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL2—atherosclerosis	1.61e-05	0.000179	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LPA—atherosclerosis	1.6e-05	0.000178	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PLG—atherosclerosis	1.6e-05	0.000178	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LPL—atherosclerosis	1.6e-05	0.000178	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PDGFB—atherosclerosis	1.6e-05	0.000178	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.59e-05	0.000177	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CD36—atherosclerosis	1.57e-05	0.000175	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AGT—atherosclerosis	1.56e-05	0.000173	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PRKCG—atherosclerosis	1.55e-05	0.000173	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BGN—atherosclerosis	1.55e-05	0.000173	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.55e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	1.54e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	1.54e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOA2—atherosclerosis	1.54e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALOX15—atherosclerosis	1.54e-05	0.000172	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.54e-05	0.000171	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CG—atherosclerosis	1.54e-05	0.000171	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOA5—atherosclerosis	1.54e-05	0.000171	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOA2—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALOX15—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APOE—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—LEP—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCG5—atherosclerosis	1.53e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SOCS3—atherosclerosis	1.52e-05	0.000169	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CAV1—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SPP1—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCG5—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APOA1—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL8—atherosclerosis	1.51e-05	0.000168	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.49e-05	0.000166	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MTHFR—atherosclerosis	1.49e-05	0.000165	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPARG—atherosclerosis	1.48e-05	0.000165	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLA2G1B—atherosclerosis	1.48e-05	0.000164	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LPA—atherosclerosis	1.47e-05	0.000164	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP3—atherosclerosis	1.46e-05	0.000163	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.46e-05	0.000163	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LPA—atherosclerosis	1.46e-05	0.000162	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARA—atherosclerosis	1.46e-05	0.000162	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ESR1—atherosclerosis	1.46e-05	0.000162	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF2—atherosclerosis	1.46e-05	0.000162	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—INS—atherosclerosis	1.46e-05	0.000162	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.45e-05	0.000161	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.44e-05	0.000161	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—F2—atherosclerosis	1.44e-05	0.00016	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALOX5—atherosclerosis	1.43e-05	0.000159	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BGN—atherosclerosis	1.43e-05	0.000159	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOB—atherosclerosis	1.41e-05	0.000157	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BGN—atherosclerosis	1.41e-05	0.000157	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AGT—atherosclerosis	1.41e-05	0.000157	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOA5—atherosclerosis	1.41e-05	0.000157	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.4e-05	0.000156	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL8—atherosclerosis	1.4e-05	0.000156	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PDGFB—atherosclerosis	1.4e-05	0.000156	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOA5—atherosclerosis	1.4e-05	0.000156	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EDN1—atherosclerosis	1.39e-05	0.000155	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOE—atherosclerosis	1.39e-05	0.000154	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL5—atherosclerosis	1.38e-05	0.000154	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CG—atherosclerosis	1.38e-05	0.000153	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CAV1—atherosclerosis	1.37e-05	0.000153	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOA1—atherosclerosis	1.37e-05	0.000152	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AGT—atherosclerosis	1.37e-05	0.000152	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.36e-05	0.000151	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	1.36e-05	0.000151	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LPL—atherosclerosis	1.35e-05	0.00015	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	1.35e-05	0.00015	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LEP—atherosclerosis	1.34e-05	0.000149	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOE—atherosclerosis	1.34e-05	0.000149	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—atherosclerosis	1.33e-05	0.000148	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.33e-05	0.000148	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CAV1—atherosclerosis	1.33e-05	0.000148	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOA1—atherosclerosis	1.32e-05	0.000147	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK3—atherosclerosis	1.32e-05	0.000147	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.32e-05	0.000147	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.32e-05	0.000147	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.32e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKCG—atherosclerosis	1.31e-05	0.000146	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALOX5—atherosclerosis	1.31e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—INS—atherosclerosis	1.31e-05	0.000145	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.3e-05	0.000145	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL2—atherosclerosis	1.28e-05	0.000143	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.28e-05	0.000142	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SPP1—atherosclerosis	1.28e-05	0.000142	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ESR1—atherosclerosis	1.28e-05	0.000142	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NOS3—atherosclerosis	1.28e-05	0.000142	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—atherosclerosis	1.27e-05	0.000142	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.27e-05	0.000142	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LIPC—atherosclerosis	1.27e-05	0.000142	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOC3—atherosclerosis	1.26e-05	0.000141	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—F2—atherosclerosis	1.26e-05	0.000141	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—atherosclerosis	1.26e-05	0.00014	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LDLR—atherosclerosis	1.26e-05	0.00014	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CG—atherosclerosis	1.25e-05	0.000139	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CETP—atherosclerosis	1.23e-05	0.000137	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—atherosclerosis	1.21e-05	0.000134	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—atherosclerosis	1.21e-05	0.000134	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.2e-05	0.000134	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SERPINE1—atherosclerosis	1.2e-05	0.000133	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PDGFB—atherosclerosis	1.18e-05	0.000132	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—INS—atherosclerosis	1.18e-05	0.000132	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAMPT—atherosclerosis	1.18e-05	0.000131	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SCARB1—atherosclerosis	1.18e-05	0.000131	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LIPC—atherosclerosis	1.17e-05	0.00013	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—atherosclerosis	1.17e-05	0.00013	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.17e-05	0.00013	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOC3—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LIPC—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LDLR—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AGT—atherosclerosis	1.16e-05	0.000129	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOC3—atherosclerosis	1.15e-05	0.000128	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LDLR—atherosclerosis	1.15e-05	0.000127	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOS3—atherosclerosis	1.14e-05	0.000127	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.14e-05	0.000127	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—INS—atherosclerosis	1.14e-05	0.000127	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOE—atherosclerosis	1.13e-05	0.000126	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—atherosclerosis	1.13e-05	0.000126	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CETP—atherosclerosis	1.13e-05	0.000126	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL2—atherosclerosis	1.13e-05	0.000125	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CAV1—atherosclerosis	1.12e-05	0.000125	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CETP—atherosclerosis	1.12e-05	0.000124	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOA1—atherosclerosis	1.12e-05	0.000124	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMGCR—atherosclerosis	1.11e-05	0.000123	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—atherosclerosis	1.11e-05	0.000123	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—atherosclerosis	1.08e-05	0.000121	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.08e-05	0.00012	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—atherosclerosis	1.08e-05	0.00012	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.07e-05	0.000119	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—F2—atherosclerosis	1.07e-05	0.000119	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—atherosclerosis	1.05e-05	0.000117	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.04e-05	0.000116	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—atherosclerosis	1.04e-05	0.000115	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.02e-05	0.000114	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.02e-05	0.000114	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—atherosclerosis	1.02e-05	0.000113	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.01e-05	0.000113	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—atherosclerosis	1e-05	0.000112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1e-05	0.000111	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCA1—atherosclerosis	9.9e-06	0.00011	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—atherosclerosis	9.81e-06	0.000109	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	9.79e-06	0.000109	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—INS—atherosclerosis	9.68e-06	0.000108	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—atherosclerosis	9.66e-06	0.000107	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL2—atherosclerosis	9.52e-06	0.000106	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—atherosclerosis	9.49e-06	0.000106	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—atherosclerosis	9.36e-06	0.000104	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—atherosclerosis	9.19e-06	0.000102	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	9.13e-06	0.000102	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCA1—atherosclerosis	9.1e-06	0.000101	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFKB1—atherosclerosis	9.09e-06	0.000101	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCA1—atherosclerosis	9.02e-06	0.0001	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK8—atherosclerosis	8.93e-06	9.93e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—atherosclerosis	8.91e-06	9.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—atherosclerosis	8.9e-06	9.9e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	8.89e-06	9.88e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—atherosclerosis	8.6e-06	9.56e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—atherosclerosis	8.49e-06	9.44e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—atherosclerosis	8.48e-06	9.43e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—atherosclerosis	8.47e-06	9.41e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—atherosclerosis	8.25e-06	9.17e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—atherosclerosis	8.17e-06	9.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOB—atherosclerosis	8.13e-06	9.04e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—atherosclerosis	8.05e-06	8.96e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFKB1—atherosclerosis	7.97e-06	8.86e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—atherosclerosis	7.91e-06	8.8e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK8—atherosclerosis	7.83e-06	8.71e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—atherosclerosis	7.81e-06	8.69e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.81e-06	8.68e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—atherosclerosis	7.8e-06	8.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LPL—atherosclerosis	7.77e-06	8.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—atherosclerosis	7.74e-06	8.61e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—atherosclerosis	7.58e-06	8.42e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—atherosclerosis	7.57e-06	8.42e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	7.53e-06	8.37e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOB—atherosclerosis	7.48e-06	8.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOB—atherosclerosis	7.42e-06	8.25e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CD36—atherosclerosis	7.38e-06	8.2e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—atherosclerosis	7.28e-06	8.09e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	7.27e-06	8.08e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	7.23e-06	8.04e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—atherosclerosis	7.21e-06	8.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—atherosclerosis	7.16e-06	7.96e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—atherosclerosis	7.16e-06	7.96e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LPL—atherosclerosis	7.14e-06	7.94e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LPL—atherosclerosis	7.08e-06	7.87e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—atherosclerosis	6.99e-06	7.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—atherosclerosis	6.97e-06	7.75e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—atherosclerosis	6.91e-06	7.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARA—atherosclerosis	6.86e-06	7.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	6.84e-06	7.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—atherosclerosis	6.81e-06	7.57e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CD36—atherosclerosis	6.79e-06	7.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	6.73e-06	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CD36—atherosclerosis	6.73e-06	7.48e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGT—atherosclerosis	6.64e-06	7.39e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	6.64e-06	7.38e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	6.62e-06	7.36e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	6.6e-06	7.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOE—atherosclerosis	6.51e-06	7.24e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAV1—atherosclerosis	6.45e-06	7.17e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOA1—atherosclerosis	6.44e-06	7.16e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—atherosclerosis	6.43e-06	7.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—atherosclerosis	6.38e-06	7.09e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARA—atherosclerosis	6.31e-06	7.02e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARA—atherosclerosis	6.26e-06	6.95e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	6.11e-06	6.8e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGT—atherosclerosis	6.11e-06	6.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGT—atherosclerosis	6.06e-06	6.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—atherosclerosis	6.05e-06	6.73e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOE—atherosclerosis	5.99e-06	6.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOE—atherosclerosis	5.94e-06	6.6e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAV1—atherosclerosis	5.93e-06	6.6e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOA1—atherosclerosis	5.92e-06	6.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAV1—atherosclerosis	5.88e-06	6.54e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—atherosclerosis	5.88e-06	6.53e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—atherosclerosis	5.87e-06	6.53e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOA1—atherosclerosis	5.87e-06	6.52e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	5.78e-06	6.43e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—atherosclerosis	5.7e-06	6.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—atherosclerosis	5.67e-06	6.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	5.61e-06	6.24e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—INS—atherosclerosis	5.56e-06	6.18e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5.4e-06	6.01e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—atherosclerosis	5.36e-06	5.96e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—atherosclerosis	5.26e-06	5.85e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—atherosclerosis	5.22e-06	5.8e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—atherosclerosis	5.17e-06	5.75e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—INS—atherosclerosis	5.12e-06	5.69e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—atherosclerosis	5.1e-06	5.67e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—INS—atherosclerosis	5.07e-06	5.64e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—atherosclerosis	5e-06	5.56e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—atherosclerosis	4.88e-06	5.42e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—atherosclerosis	4.77e-06	5.3e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—atherosclerosis	4.69e-06	5.21e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—atherosclerosis	4.65e-06	5.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—atherosclerosis	4.61e-06	5.13e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—atherosclerosis	4.49e-06	4.99e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—atherosclerosis	4.46e-06	4.96e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—atherosclerosis	4.45e-06	4.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—atherosclerosis	4.23e-06	4.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—atherosclerosis	4.1e-06	4.56e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—atherosclerosis	4.07e-06	4.52e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—atherosclerosis	3.9e-06	4.34e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—atherosclerosis	2.24e-06	2.49e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—atherosclerosis	2.06e-06	2.29e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—atherosclerosis	2.04e-06	2.27e-05	CbGpPWpGaD
